Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
Traditionally, non-small cell lung cancer is treated as a single disease entity in terms of systemic therapy. Emerging evidence suggests the major subtypes--adenocarcinoma (AC) and squamous cell carcinoma (SqCC)--respond differently to therapy. Identification of the molecular differences between the...
Main Authors: | William W Lockwood, Raj Chari, Bradley P Coe, Kelsie L Thu, Cathie Garnis, Chad A Malloff, Jennifer Campbell, Ariane C Williams, Dorothy Hwang, Chang-Qi Zhu, Timon P H Buys, John Yee, John C English, Calum Macaulay, Ming-Sound Tsao, Adi F Gazdar, John D Minna, Stephen Lam, Wan L Lam |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-07-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC2910599?pdf=render |
Similar Items
-
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
by: William W Lockwood, et al.
Published: (2012-01-01) -
Genetic alteration and gene expression modulation during cancer progression
by: Lam Wan L, et al.
Published: (2004-03-01) -
Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.
by: Bradley P Coe, et al.
Published: (2013-01-01) -
The role of BRF1 and BRF2 in the immune response
by: Crawford, Rebecca
Published: (2008) -
Brf Norrby
by: Alenby Löfstaf, Sara
Published: (2021)